Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns'
epigenetic biological aging. The patients are being tested at baseline, halfway point, and
after the trial period.